Trial record 1 of 3 for:    CLBH589BUS48T
Previous Study | Return to List | Next Study

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) (BUS48T)

This study has been completed.
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Anand Jillella, Georgia Regents University
ClinicalTrials.gov Identifier:
NCT01504776
First received: August 8, 2011
Last updated: September 18, 2014
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2014
  Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)